Cart
sales@molnova.com
ATH 686
CAS No. 853299-52-2
ATH 686( —— )
Catalog No. M20993 CAS No. 853299-52-2
ATH 686 is an potent and selective Inhibitor of FLT3.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 295 | Get Quote |
|
| 10MG | 500 | Get Quote |
|
| 25MG | 804 | Get Quote |
|
| 50MG | 1098 | Get Quote |
|
| 100MG | 1485 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameATH 686
-
NoteResearch use only, not for human use.
-
Brief DescriptionATH 686 is an potent and selective Inhibitor of FLT3.
-
DescriptionATH 686 is an potent and selective Inhibitor of FLT3.
-
In VitroATH686 (1-100 μM; 3 days) potently inhibits cell proliferation (IC50 around 0.001 μM) via induction of apoptosis in FLT3-ITD-Ba/F3 cells and D835Y-Ba/F3 cells. ATH686 (10 nM; for 15 minutes) inhibits autophosphorylation of mutant FLT3 in FLT3-ITD-Ba/F3 cells. Cell Proliferation Assay Cell Line:FLT3-ITD-Ba/F3 cells and D835Y-Ba/F3 cells Concentration:1, 5, 10, 50, 100 μM Incubation Time:3 days Result:Potently inhibited cell proliferation (IC50 around 0.001 μM) via induction of apoptosis.Western Blot Analysis Cell Line:FLT3-ITD-Ba/F3 cells Concentration:10 nM Incubation Time:For 15 minutes Result:Inhibited autophosphorylation of mutant FLT3, with no apparent reduction in levels of the FLT3 protein.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFLT
-
RecptorFLT3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number853299-52-2
-
Formula Weight515.53
-
Molecular FormulaC25H28F3N7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (484.94 mM)
-
SMILESCCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4ccnc(N)n4)cc3)cc2C(F)(F)F)CC1
-
Chemical Name1-[4-(2-Amino-pyrimidin-4-yloxy)-phenyl]-3-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-urea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Weisberg E Roesel J Furet P Bold G Imbach P Fl?rsheimer A Caravatti GJiang J Manley P Ray A Griffin JD. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer.2010 Oct;1(10):1021-32.
molnova catalog
related products
-
Emavusertib
Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
-
HM43239 B
HM43239 is an orally active and selective FLT3 inhibitor with IC 50 s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively.
-
Gilteritinib hemifum...
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML.
